CN1586519A - Chinese medicine for treating women's chronic pelvic infection - Google Patents
Chinese medicine for treating women's chronic pelvic infection Download PDFInfo
- Publication number
- CN1586519A CN1586519A CN 200410060184 CN200410060184A CN1586519A CN 1586519 A CN1586519 A CN 1586519A CN 200410060184 CN200410060184 CN 200410060184 CN 200410060184 A CN200410060184 A CN 200410060184A CN 1586519 A CN1586519 A CN 1586519A
- Authority
- CN
- China
- Prior art keywords
- present
- treatment
- radix
- chinese medicine
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 230000001684 chronic effect Effects 0.000 title claims abstract description 19
- 206010058674 Pelvic Infection Diseases 0.000 title abstract 4
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 46
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 33
- 239000008187 granular material Substances 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 208000024891 symptom Diseases 0.000 abstract description 13
- 241000722118 Thlaspi Species 0.000 abstract description 10
- 230000001154 acute effect Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000017303 Althaea rosea Nutrition 0.000 abstract 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 abstract 1
- 241001146155 Emilia Species 0.000 abstract 1
- 235000019049 Emilia coccinea Nutrition 0.000 abstract 1
- 241000218033 Hibiscus Species 0.000 abstract 1
- 235000017881 Hibiscus moscheutos subsp moscheutos Nutrition 0.000 abstract 1
- 229930184510 Mallotus Natural products 0.000 abstract 1
- 241001060384 Mallotus <angiosperm> Species 0.000 abstract 1
- 241000157511 Oldenlandia Species 0.000 abstract 1
- 235000007234 Rhodomyrtus tomentosa Nutrition 0.000 abstract 1
- 240000007994 Rhodomyrtus tomentosa Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 235000007180 rose mallow Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003119 painkilling effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 241000746375 Andrographis Species 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000004145 Endometritis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000288027 Chrysolophus pictus Species 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001407408 Berberis fortunei Species 0.000 description 1
- 241001098027 Callerya speciosa Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001528553 Malus asiatica Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Chinese medicine technology, and discloses one kind of Chinese medicine for treating women's chronic pelvic infection. The Chinese medicine consists of active components from the Chinese medicinal materials tassel flower herb, oldenlandia, rose mallow root or herb, white backleaf mallotus root, Herba thlaspis, spatholobus stem and downy rosemyrtle root. When used in treating women's chronic pelvic infection, the medicine can remit the clinical symptoms and improve patient's physical sign. It has also obvious effect of treating acute and subacute pelvic infection.
Description
Technical field
The present invention relates to technical field of Chinese medicines, especially a kind of Chinese medicine preparation that is used for the treatment of women's chronic pelvic inflammatory disease.
Background technology
Pelvic inflammatory disease is a common gynecological disease, comprises the inflammation of pelvic cavity genitals (uterus body, fallopian tube, ovary) and pelvic peritoneum and periuterine connective tissue.Being born in property of pelvic inflammatory disease pilosity active phase women, 21-30 year is a pelvic inflammatory disease age bracket occurred frequently.There is survey data to show: in the common gynaecopathia case, the overall sickness rate of chronic pelvic pain is 16.9%, and the overall cause of disease constitutes the highest with pelvic inflammatory disease, is 40.3%, in the chronic pelvic inflammatory disease fertility person's sickness rate be 33.1%, nullipara's sickness rate is 56.7%.After getting, pelvic inflammatory disease can cause oviducal adhesion, logical and not smooth, perhaps obstructed with regard to causing fallopian tube like this, so just cause infertility.Also have survey data to show: the course of disease is among the sterility and infertility patient in 1 year～13 years, and sterility and infertility accounts for and checks unusual person's 63.8% due to the salpingitis.Therefore, pelvic inflammatory disease is one of common frdquently encountered disease disease that influences women's work, studying and living, how to treat female pelvic inflammation effectively and has crucial meaning.The treatment female pelvic inflammation can be divided into western medical treatment and Chinese traditional treatment, and has extract oral, the external application of Chinese medicine, herbal enema, Chinese medicine drop, tcm herbal ion to import in the Chinese traditional treatment, can also cooperate several different methods such as acupuncture.Wherein the Chinese patent medicine oral medication is an important aspect, and to the in-and-out chronic pelvic inflammatory disease of some symptoms, the patient who eats the decoction inconvenience for a long time is particularly suitable.Aspect middle one-tenth oral medicine, at qi depression to blood stasis, the various causes of disease damp and hot, cold and heat, the medicine that has different raw material of Chinese medicine to make arranged.The existing effective Chinese patent medicine that can be used for treating the damp and hot stasis of blood combined symptoms of women's chronic pelvic inflammatory disease comprises: " JINJI PIAN ", " JINJI KELI " and " JINJI JIAONANG " just like " FUKE QIANJIN PIAN " and the golden pheasant series of products of Guangxi China Ling Feng Peak pharmaceutcal corporation, Ltd production that Chinese Zhuzhou Qianjin Pharmacy Co., Ltd produces.
FUKE QIANJIN PIAN is made by raw material of Chinese medicine such as Radix Codonopsis, Radix Angelicae Sinensis, Radix Rosae Laevigatae, Radix Flemingiae Philippinensis, Caulis Mahoniae, Herba Andrographis, Caulis Spatholobis.Function cures mainly: removing damp-heat, benefiting vital QI and blood.Be used for leukorrheal diseases, damp invasion of lower energizer, insufficiency of vital energy and blood disease, and disease such as pelvic inflammatory disease, endometritis.Radix Flemingiae Philippinensis is commonly called as Herba Fici Simplicissimae in the side, calls Pheretima, Millettia Speciosa, winged steed, the strong waist knee joint of effect, and the meridian dredging, blood circulation promoting and blood stasis dispelling is principal agent, Radix Rosae Laevigatae, Mahonia fortunei (Lindl.) Fedde, Fructus Zanthoxyli Dissiti, Herba Andrographis clearing away heat and cooling blood, detoxification and promoting urination; Radix Angelicae Sinensis, Caulis Spatholobi nourshing blood and promoting blood circulation, Radix Codonopsis replenishing QI to invigorate the spleen are set upright.All medicines are harmonious.Play heat-clearing and toxic substances removing, benefiting QI and nourishing blood altogether, the effect of blood circulation promoting and blood stasis dispelling.The clinical leukorrheal diseases, pelvic inflammatory disease, endometritis, cervicitis of being used for belong to damp invasion of lower energizer, insufficiency of vital energy and blood disease person.This medicine shows through doing contrast test: the total effective rate to chronic pelvic inflammatory disease dampness and heat stasis disease patient's doing well,improving is 72.72% (P＞0.05), and total cure-remarkable-effectiveness rate is 9.00% (P＞0.05); Traditional Chinese medical science disease curative effect total effective rate is 68.18% (P＞0.05), and total cure-remarkable-effectiveness rate is 9.00% (P＞0.05); Local sign treatment total effective rate is 68.18% (P＞0.05), and total cure-remarkable-effectiveness rate is 13.63% (P＞0.05).
The golden pheasant series of products are made up of Radix Rosae Laevigatae, Caulis Spatholobi, Radix Flemingiae Philippinensis, Caulis Mahoniae, Radix Zanthoxyli, Herba Andrographis etc.Function cures mainly: heat-clearing and toxic substances removing, and the spleen invigorating dehumidifying, collateral dredging is invigorated blood circulation.Be used for diseases such as adnexitis that damp invasion of lower energizer causes, endometritis, pelvic inflammatory disease.
The existing Chinese patent medicine that is used for the treatment of female pelvic inflammation, still not ideal enough aspect therapeutic effect.
Summary of the invention
Problem to be solved by this invention is to overcome above-mentioned weak point, the Chinese patent medicine of the treatment female pelvic inflammation of research design better efficacy.
The invention provides a kind of Chinese medicine that is mainly used in the treatment women's chronic pelvic inflammatory disease, it more significantly the relieve chronic pelvic inflammatory disease clinical symptoms and improve patient's sign, have remarkable result aspect acute, the subacute pelvic inflammatory disease of treatment.
For achieving the above object, the Chinese medicine of this treatment women's chronic pelvic inflammatory disease is formed as active ingredient and pharmaceutic adjuvant by comprising following materials of weight proportions: Herba Duchesneae Indicae 13～23, Herba Hedyotidis Diffusae 5～15, Radix Urenae Lobatae 13～23, Radix Malloti Apelitae 5～15 Herba Thlaspiss 5～15, Caulis Spatholobi 10～20, Radix Rhodomyrti 13～23.
The various raw materials that the present invention is contained can adopt existing conventional Chinese patent medicine manufacturing process to add the conventional adjuvant of medicament and make as the above peroral dosage form of any modern medicinal agents such as tablet, granule, pill, capsule, oral liquid.
In the above-mentioned prescription, Herba Duchesneae Indicae is cool in nature, mildly bitter flavor, heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling, sweet, cold in nature, the clearing away heat-damp and promoting diuresis of the little hardship of Herba Hedyotidis Diffusae, removing toxic substances and promoting subsidence of swelling pain relieving, two medicines share, its clearing away heat-damp and promoting diuresis, the merit of stasis-dispelling and pain-killing is more remarkable, and dampness-heat in the spleen can be clearly, stasis of blood pain can be ended, so clinical practice has good effect in all diseases of female pelvic inflammation, be the monarch drug in the side altogether.
The Radix Urenae Lobatae sugariness is flat in the above-mentioned prescription, clearing away heat-damp and promoting diuresis detoxifcation, promoting blood circulation and detumescence pain relieving; Radix Malloti Apelitae, mildly bitter flavor, property are put down clearing away heat-damp and promoting diuresis, promoting blood circulation and detumescence; Herba Thlaspis, bitter sweet flat, heat-clearing and toxic substances removing, inducing diuresis to remove edema.Three medicines share, and the merit of in addition strong monarch drug clearing away heat-damp and promoting diuresis, stasis-dispelling and pain-killing can strengthen the curative effect of all diseases of treatment pelvic inflammatory disease, are the ministerial drug in the side altogether.
Caulis Spatholobi in the above-mentioned prescription, bitter in the mouth, little sweet, property is steady, promoting the circulation of blood is enriched blood, defeated channels and activating collaterals, for diseases such as menoxenia, amenorrhea, dysmenorrhea commonly used; The Radix Rhodomyrti sweet in the mouth, little acid, property is flat, astringing to arrest bleeding, and removing obstruction in the collateral to relieve pain is also used always by gynaecopathia.Two medicines share, and can help the merit of all medicine stasis-dispelling and pain-killings of the monarch and his subjects, are to be the adjuvant drug in the side.
Respectively distinguish the flavor of among the present invention combination of medicine can make this medical instrument that clearing away heat-damp and promoting diuresis, stasis-dispelling and pain-killing are arranged, and is used for the women and hinders because of damp and hot harmony, all diseases of pelvic inflammatory disease due to QI and blood is retarded by silt.
Owing to adopted such scheme, the present invention compared with prior art has following beneficial effect:
Therapeutic effect is obvious.The FUKE QIANJIN PIAN that tablet of the present invention and Chinese Zhuzhou Qianjin Pharmacy Co., Ltd produce shows complying clinical observation experiment (tablet wherein of the present invention observation group 50 examples, FUKE QIANJIN PIAN matched group 22 examples):
1, two groups of general curative effects relatively: tablet total effective rate of the present invention is 88%, and total cure-remarkable-effectiveness rate is 36%; Traditional Chinese medical science sign curative effect total effective rate is 86%, and total cure-remarkable-effectiveness rate is 40%; Local sign treatment total effective rate is 88%, and total cure-remarkable-effectiveness rate is 38%.The FUKE QIANJIN PIAN total effective rate is 72.72%, and total cure-remarkable-effectiveness rate is 9%; Traditional Chinese medical science sign curative effect total effective rate is 68.18%, and total cure-remarkable-effectiveness rate is 9%; Local sign treatment total effective rate is 68.18%, and total cure-remarkable-effectiveness rate is 13.63%.There were significant differences (P＜0.05) for total cure-remarkable-effectiveness rate between two groups, total effective rate there was no significant difference (P＞0.05); The total cure-remarkable-effectiveness rate of traditional Chinese medical science sign has significant difference (P＜0.05) for two groups, total effective rate there was no significant difference (P＞0.05); There were significant differences (P＜0.05) for the total cure-remarkable-effectiveness rate of local sign curative effect; Local sign curative effect total effective rate there was no significant difference (P＞0.05).
2, two groups of treatment front and back symptoms relatively: observation group, matched group are treated precursor symptom integration and are respectively 20.80 ± 5.57,18.40 ± 5.81; Treat the back symptom integral and be respectively 8.50 ± 4.67,11.45 ± 6.80.Before two groups of treatment back symptom integral are starkly lower than and treat (P＜0.05), relatively, treat back treatment group symptom integral and be starkly lower than matched group (P＞0.05) between two groups.
3, two groups of treatment front and back signs relatively: the sign integration was respectively 7.72 ± 3.11,6.54 ± 2.78 before observation group, matched group were treated; Treat back sign integration and be respectively 2.28 ± 2.26,3.90 ± 2.38.Before two groups of treatment back sign integrations are starkly lower than and treat (P＜0.05), but compare not statistically significant (P＞0.05) between two groups.
4, two groups of treatment front and back total white blood cellses change relatively: observation group, matched group are treated the proleukocyte sum and are respectively 6.51 ± 1.93,5.92 ± 1.20; Treat the back total white blood cells and be respectively 5.84 ± 1.61,6.63 ± 1.76.Treat after preceding the treatment and between two groups for two groups and compare not statistically significant (P＞0.05).
5, two groups of treatment front and back neutrophilic leukocytees change relatively: neutrophilic leukocyte was respectively 64.65 ± 7.24,61.32 ± 7.24 before observation group, matched group were treated; Treat back neutrophilic leukocyte and be respectively 62.99 ± 7.36,63.74 ± 9.95.Treat after preceding the treatment and between two groups for two groups and compare not statistically significant (P＞0.05).
6, two groups of treatment front and back hematochrome change relatively: hematochrome was respectively 133.00 ± 12.36,101.45 ± 43.39 before observation group, matched group were treated; Treat back hematochrome sum and be respectively 130.63 ± 11.22,114.86 ± 36.48.Treat after preceding the treatment and between two groups for two groups and compare not statistically significant (P＞0.05).
7, two groups of treatment front and back pelvic hydropies change relatively: pelvic hydrops was respectively 0.28 ± 0.59,0.11 ± 0.33 before observation group, matched group were treated; Treat back pelvic hydrops sum and be respectively 0.14 ± 0.29,0.10 ± 0.32.Treat after preceding the treatment and between two groups for two groups and compare not statistically significant (P＞0.05).
The result: tablet group of the present invention, FUKE QIANJIN PIAN group total effective rate are respectively 88.00%, 72.72% (P＞0.05), and total cure-remarkable-effectiveness rate is respectively 36.00%, 9.00% (P＞0.05); Traditional Chinese medical science sign curative effect total effective rate is respectively 86.00%, 68.18% (P＞0.05), and total cure-remarkable-effectiveness rate is respectively 40%, 9.00% (P＜0.05); Local sign curative effect total effective rate is respectively 88.00%, 68.18% (P＞0.05), and total cure-remarkable-effectiveness rate is respectively 38.00%, 13.63% (P＞0.05).Two groups of treatment back sign scorings all are starkly lower than treatment preceding (P＞0.05).Conclusion: tablet of the present invention and FUKE QIANJIN PIAN are effective Chinese patent medicine of the damp and hot stasis of blood knot of treatment chronic pelvic inflammatory disease card, the two is improving effect similar (P＞0.05) aspect the sign of chronic pelvic inflammatory disease, and tablet of the present invention obviously is better than FUKE QIANJIN PIAN (P＞0.05) to chronic pelvic inflammatory disease syndrome of stagnant dampness-heat patient's doing well,improving.
It is as follows that tablet, capsule, the granule that the various raw materials that the present invention is contained are made carries out the therapeutic effect of clinical comparison:
1, Therapeutic Method:
Determine treatment group and matched group case with simple random sampling, select for use " granule of the present invention " to do the matched group medicine." tablet of the present invention " treatment group totally 104 examples wherein, " capsule of the present invention " treatment group is totally 107 examples, and " granule of the present invention " matched group is totally 107 examples.Each is organized case and derives from four hospitals, sees Table 1.
Table 1: unit: example
| One attached institute of Guangxi institute of traditional Chinese medicine | ??20 | ??22 | ??20 | ??62 |
| Amount to | ??104 | ??107 | ??107 | ??318 |
2, treatment standard: be divided into level Four.
Cure: subjective symptoms disappears, positive sign disappears substantially.
Produce effects: subjective symptoms disappears substantially, positive sign is clearly better.
Take a turn for the better: subjective symptoms alleviates, positive sign takes a turn for the better.
Invalid: symptom, sign no change.
3, result.
(1) " tablet of the present invention ", " capsule of the present invention ", " granule of the present invention " curative effect relatively see Table 2.
Table 2
From table 2, the effective percentage of " tablet of the present invention ", " capsule of the present invention ", " granule of the present invention " all reaches 100%, wherein, it is 92.3% that the healing of " tablet of the present invention " adds obvious effective rate, it is 89.2% that " capsule of the present invention " healing adds produce effects, it is relatively (P＞0.05) equal no significant difference of 87.85%, three kind of dosage form curative effect that " granule of the present invention " healing adds produce effects, illustrates that curative effect is all fine.
(2), " tablet of the present invention " of different course, " capsule of the present invention " relatively see Table 3 with the curative effect of " granule of the present invention ".
Table 3
| Granule of the present invention | 107 | 25 | 23.36 | 21 | 19.62 | 56 | 52.33 | 5 | 4.67 | |
| Second course of treatment | Tablet of the present invention | 79 | 37 | 46.83 | 24 | 30.37 | 18 | 22.78 | ||
| Capsule of the present invention | 96 | 35 | 36.45 | 37 | 38.54 | 24 | 25.00 | |||
| Granule of the present invention | 82 | 27 | 32.92 | 25 | 30.48 | 29 | 35.36 | 1 | 1.21 | |
| The 3rd course of treatment | Tablet of the present invention | 42 | 26 | 61.90 | 8 | 19.04 | 8 | 19.04 | ||
| Capsule of the present invention | 61 | 34 | 55.73 | 15 | 24.59 | 12 | 19.67 | |||
| Granule of the present invention | 58 | 29 | 50.00 | 14 | 24.14 | 15 | 25.86 |
First course of treatment: " tablet of the present invention " compares P＞0.05 with " granule of the present invention " effective percentage, and " capsule of the present invention " compares 0.01＜P＜0.05 with " granule of the present invention " effective percentage.
Second course of treatment: " tablet of the present invention " compares P＜0.01 with " granule of the present invention " effective percentage; " capsule of the present invention " compares P＞0.05 with " granule of the present invention " effective percentage;
The 3rd course of treatment: " tablet of the present invention ", " capsule of the present invention " and " granule of the present invention " more equal P＞0.05.More than three kinds of curative effect of medication of explanation different course all do not have significant difference.
(3), " tablet of the present invention ", " capsule of the present invention " curative effect and relationship with age see Table 4.
Table 4, " tablet of the present invention " and relationship with age
| Age | Subtotal | Cure | Produce effects | Take a turn for the better | Invalid | ||||
| Example | ％ | Example | ％ | Example | ％ | Example | ％ | ||
| 20～29 | 26 | 23 | 88.46 | 1 | 3.85 | 2 | 7.69 | ||
| 30～39 | 63 | 55 | 87.30 | 2 | 3.17 | 6 | 9.52 | ||
| 40～49 | 11 | 9 | 81.82 | 2 | 18.18 | ||||
| More than 50 | 4 | 1 | 25 | 3 | 75.00 | ||||
| Add up to | 104 | 88 | 84.62 | 8 | 7.69 | 8 | 7.69 | ||
Table 5, " capsule of the present invention " and relationship with age
| Age | Subtotal | Cure | Produce effects | Take a turn for the better | Invalid | ||||
| Example | ％ | Example | ％ | Example | ％ | Example | ％ | ||
| 20～29 | 35 | 24 | 68.57 | 6 | 17.14 | 5 | 14.28 | ||
| 30～39 | 61 | 46 | 75.40 | 9 | 14.75 | 6 | 9.83 | ||
| 40～49 | 9 | 9 | 100 | ||||||
| More than 50 | 2 | 1 | 50 | 1 | 50 | ||||
| Add up to | 107 | 80 | 74.76 | 16 | 14.95 | 11 | 10.28 |
" tablet of the present invention " compares P＞0.05, no significant difference with " capsule of the present invention " treatment and each age group in the table 4,5.
(4), " tablet of the present invention " and " capsule of the present invention " curative effect and course of disease relation:
Table 8: " tablet of the present invention " and course of disease relation
| The course of disease | Subtotal | Cure | Produce effects | Take a turn for the better | Invalid | ||||
| Example | ％ | Example | ％ | Example | ％ | Example | ％ | ||
| Less than 1 year | 54 | 47 | 87.04 | 4 | 7.41 | 3 | 5.56 | ||
| One to two year | 12 | 12 | 100 | 5.56 | |||||
| Two to three years | 18 | 16 | 88.89 | 1 | 28.57 | 1 | 5.56 | ||
| Three to four years | 7 | 4 | 57.14 | 2 | 11.11 | 1 | 14.29 | ||
| Four to five years | 4 | 4 | 100 | 7.69 | |||||
| More than 5 years | 9 | 5 | 55.56 | 1 | 3 | 33.33 | |||
| Add up to | 104 | 88 | 84.60 | 8 | 4 | 7.69 | |||
(5) blood routine examination result:
Because " tablet of the present invention ", " capsule of the present invention " are same prescription with " granule of the present invention ", in " HUAHONG KELI " checking, hemorrhage, urine, liver, renal function and blood pressure inspection have been done, all do not have obviously before and after the treatment and change, so blood routine examination is only done in the current clinical verification of " tablet of the present invention ", " capsule of the present invention ", consequently: in 211 example treatments, hemoglobin 28 examples that have more than 19 that rise, account for 21 examples that have of 13.2% hemoglobin decline, account for 9.95%, but all fluctuate in normal range.1000～3000/mm of leukocyte rising
350 examples are arranged, account for 23.6%, 1000～3000/mm descends
343 examples, account for 20.37%.Wherein surpass 10,000/mm
36 examples are arranged, be lower than 4000/mm
34 examples are arranged, sum was at 5000/mm before this 4 example was all treated
3Very fast recovery is normal behind the following drug withdrawal first quarter moon.
The specific embodiment
Be described in further detail below in conjunction with the Chinese medicine of application example this treatment women's chronic pelvic inflammatory disease:
Embodiment 1: make every 280 milligrams 1000 in tablet of the present invention:
1, raw material is formed Herba Duchesneae Indicae 1250g, Herba Hedyotidis Diffusae 750g, Radix Urenae Lobatae 1250g, Radix Malloti Apelitae 750g, Herba Thlaspis 750g, Caulis Spatholobi 1000g, Radix Rhodomyrti 1250g, hydroxypropyl emthylcellulose 20g, Pulvis Talci 35g, magnesium stearate 12.5g.
2, method for making: Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae Herba Thlaspis, Radix Rhodomyrti, Caulis Spatholobi is the seven flavor medicine material altogether, get 14% Herba Duchesneae Indicae medical material, be ground into fine powder, Six-elements such as remaining Herba Duchesneae Indicae and remaining Herba Hedyotidis Diffusae, decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, merge decoction liquor, filter, filtrate is concentrated into the clear paste of relative density 1.18～1.23 (80 ℃), and adding ethanol is 65% (g/g) to containing the alcohol amount, stir evenly, left standstill 24 hours, and filtered, decompression filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.25～1.30 (80 ℃), add above-mentioned fine powder and small amount of adhesive, mixing is made granule, drying, be pressed into 1000, behind the sugar coating promptly.
Embodiment 2: make 250 milligrams every 1000 of capsules of the present invention:
1, raw material is formed: Herba Duchesneae Indicae 2500g, Herba Hedyotidis Diffusae 1500g, Radix Urenae Lobatae 2500g, Radix Malloti Apelitae 1500g, Herba Thlaspis 1500g, Caulis Spatholobi 2000g, Radix Rhodomyrti 2500g, starch 60g, microcrystalline Cellulose 10g, magnesium stearate 10g.
2, method for making: Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae Herba Thlaspis, Radix Rhodomyrti, Caulis Spatholobi is seven flavor medicine material extracting in water secondary altogether, 2 hours for the first time, 1.5 hours for the second time, merge decoction liquor, filter, filtrate is concentrated into the clear paste that relative density is 1.18～1.23 (80 ℃), add ethanol and reach 65% to containing the alcohol amount, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.25～1.30 (80 ℃), drying is ground into fine powder, adds right amount of auxiliary materials, mixing, make granule, drying is divided equally 1000 capsules of packing into and is made.
Embodiment 3: 1000 bags of granules of the present invention making every bag 10 gram:
1, raw material is formed: Herba Duchesneae Indicae 5000g, Herba Hedyotidis Diffusae 3000g, Radix Urenae Lobatae 5000g, Radix Malloti Apelitae 3000g, Herba Thlaspis 3000g, Caulis Spatholobi 4000g, Radix Rhodomyrti 5000g, white sugar 10000g.
2, method for making: Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Radix Rhodomyrti, Caulis Spatholobi be the seven flavor medicine material altogether, decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, merge decoction liquor, filter, filtrate is concentrated into relative density 1.20 (80 ℃), adding ethanol is 65% (g/g) to containing the alcohol amount, stir evenly, left standstill 24 hours, filter, decompression filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.25～1.30 (80 ℃), it is an amount of to add cane sugar powder, and mixing is made granule, drying is divided equally 1000 packaging bags of packing into and is made.
Embodiment 4: make 10 milliliters every bottle 1000 bottles of oral liquids of the present invention
1, raw material is formed: Herba Duchesneae Indicae 5600g, Herba Hedyotidis Diffusae 3350g, Radix Urenae Lobatae 5600g, Radix Malloti Apelitae 3350g, Herba Thlaspis 3350g, Caulis Spatholobi 4500g, Radix Rhodomyrti 5600g, sorbitol 4500g, sodium benzoate 3g, purified water 10000ml.
2, method for making: Herba Duchesneae Indicae, Herba Hedyotidis Diffusae, Radix Urenae Lobatae, Radix Malloti Apelitae, Herba Thlaspis, Radix Rhodomyrti, Caulis Spatholobi be the seven flavor medicine material altogether, decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, merge decoction liquor, filter, filtrate is concentrated into relative density 1.20 (80 ℃), and adding ethanol is 65% (g/g) to containing the alcohol amount, stir evenly, left standstill 24 hours, and filtered, decompression filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.25～1.30 (80 ℃).Add sorbitol 4500g, sodium benzoate 3g, purified water 10000ml, heated and boiled stirs, and leaves standstill 24 hours, filters, and potting becomes 1000 bottles, and sterilization promptly.
Claims (2)
1, a kind of Chinese medicine preparation for the treatment of women's chronic pelvic inflammatory disease, it is characterized in that it forms as active ingredient and pharmaceutic adjuvant by comprising following materials of weight proportions: Herba Duchesneae Indicae 13～23, Herba Hedyotidis Diffusae 5～15, Radix Urenae Lobatae 13～23, Radix Malloti Apelitae 5～15 Herba Thlaspiss 5～15, Caulis Spatholobi 10～20, Radix Rhodomyrti 13～23.
2, the Chinese medicine preparation of treatment women's chronic pelvic inflammatory disease according to claim 1 is characterized in that described medicament comprises tablet, capsule, granule or oral liquid formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060184 CN1259078C (en) | 2004-07-08 | 2004-07-08 | Chinese medicine for treating women's chronic pelvic infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060184 CN1259078C (en) | 2004-07-08 | 2004-07-08 | Chinese medicine for treating women's chronic pelvic infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1586519A true CN1586519A (en) | 2005-03-02 |
| CN1259078C CN1259078C (en) | 2006-06-14 |
Family
ID=34603439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410060184 Expired - Lifetime CN1259078C (en) | 2004-07-08 | 2004-07-08 | Chinese medicine for treating women's chronic pelvic infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1259078C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698697B (en) * | 2005-06-02 | 2010-05-05 | 广西花红药业有限责任公司 | Slow release tablet for treating woman chronic pelvic inflammatory disease and preparation method thereof |
| CN1853687B (en) * | 2005-04-29 | 2010-05-12 | 广西花红药业有限责任公司 | Use of safflower composition for preparing medicine for treating urinary tract infection |
| CN101209299B (en) * | 2006-12-27 | 2011-05-25 | 广西壮族自治区花红药业股份有限公司 | Chinese medicinal composition for treating pelvic inflammatory disease and extracting method thereof |
| CN101444563B (en) * | 2008-11-24 | 2011-06-29 | 暨南大学 | Usage of cherokee rose root extract |
| CN106176939A (en) * | 2016-08-05 | 2016-12-07 | 逄素燕 | A kind of Chinese medicine preparation treating chronic pelvic inflammatory disease |
| CN107050359A (en) * | 2017-06-22 | 2017-08-18 | 广西中医药大学 | Treat strong medicine preparation of chronic pelvic inflammatory disease sequelae and preparation method thereof |
-
2004
- 2004-07-08 CN CN 200410060184 patent/CN1259078C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853687B (en) * | 2005-04-29 | 2010-05-12 | 广西花红药业有限责任公司 | Use of safflower composition for preparing medicine for treating urinary tract infection |
| CN1698697B (en) * | 2005-06-02 | 2010-05-05 | 广西花红药业有限责任公司 | Slow release tablet for treating woman chronic pelvic inflammatory disease and preparation method thereof |
| CN101209299B (en) * | 2006-12-27 | 2011-05-25 | 广西壮族自治区花红药业股份有限公司 | Chinese medicinal composition for treating pelvic inflammatory disease and extracting method thereof |
| CN101444563B (en) * | 2008-11-24 | 2011-06-29 | 暨南大学 | Usage of cherokee rose root extract |
| CN106176939A (en) * | 2016-08-05 | 2016-12-07 | 逄素燕 | A kind of Chinese medicine preparation treating chronic pelvic inflammatory disease |
| CN107050359A (en) * | 2017-06-22 | 2017-08-18 | 广西中医药大学 | Treat strong medicine preparation of chronic pelvic inflammatory disease sequelae and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1259078C (en) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100344313C (en) | Chinese patent drug for treating infantile cold and repeated cold, and its prepn. method | |
| CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1966052A (en) | Tablet containing red sage root and astragalus root for removing blood stasis and preparation process thereof | |
| CN1259078C (en) | Chinese medicine for treating women's chronic pelvic infection | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN102940757B (en) | Medicine composition for treating diabetic foot | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN102940693B (en) | Medicine composition for treating diabetic foot | |
| CN1318378A (en) | Heat syndrome treating Chinese medicine | |
| CN101628096B (en) | Traditional Chinese medicine composition for treating infantile diarrhea | |
| CN114366776A (en) | Traditional Chinese medicine preparation for treating infantile aphtha and preparation method thereof | |
| CN1814194B (en) | Chinese-western medicine composition for treating infant's common cold and preparation method thereof | |
| CN102940743B (en) | Medicine composition for treating diabetic foot | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1265818C (en) | Leech capsule | |
| CN1814217A (en) | Chinese medicine composition for treating rheumatoid arthritis and use thereof | |
| CN1269518C (en) | Compound medicine for treating tuberculosis and its preparing method | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN101874877A (en) | Medicine combination for promoting blood circulation and removing blood stasis and preparation method thereof | |
| CN1899416A (en) | Chinese medicine composition for treating rheumatism and its use | |
| CN1720937A (en) | Capsule for treating rheumatism and rheumatoid diseases and scapulohumeral periarthritis and preparation method thereof | |
| CN105232991A (en) | Medicine composition for treating gastric mucosal lesion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: GUANGXI HUAHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: HUAHONG PHARMACEUTICAL CO., LTD., GUANGXI |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 545007 No. 74 Hongguang Road, the Guangxi Zhuang Autonomous Region, Liuzhou Patentee after: HUAHONG PHARMACEUTICAL Co.,Ltd. GUANGXI ZHUANG AUTONOMOUS REGION Address before: 545007 No. 74 Hongguang Road, the Guangxi Zhuang Autonomous Region, Liuzhou Patentee before: Guangxi Huahong Pharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 545007 No. 74 Hongguang Road, the Guangxi Zhuang Autonomous Region, Liuzhou Patentee after: Huahong Pharmaceutical Group Co.,Ltd. of Guangxi Zhuang Autonomous Region Address before: 545007 No. 74 Hongguang Road, the Guangxi Zhuang Autonomous Region, Liuzhou Patentee before: HUAHONG PHARMACEUTICAL Co.,Ltd. GUANGXI ZHUANG AUTONOMOUS REGION |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060614 |